Ryan, Donna H.

Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes

Bray, G. A., & Ryan, D. H. (2021) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 148

Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings: Results of the Louisiana Obese Subjects Study

Ryan, D. H. (2010) · Archives of Internal Medicine

Pharmacology and Obesity TreatmentObesity and Health Practices

Cited by 143

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss

Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 142

Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

Diabetes Prevention Program Research Group, Nathan, D. M., Knowler, W. C., Edelstein, S., Crandall, J. P., Dabelea, D., Goldberg, R. B., Kahn, S. E., Mather, K. J., Trandafirescu, G., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

Drug Treatment of the Overweight Patient

Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 115

Effects of Tyrosine, Phentermine, Caffeined-amphetamine, and Placebo on Cognitive and Motor Performance Deficits During Sleep Deprivation

Magill, R. A., Waters, W. F., Bray, G. A., Volaufova, J., Smith, S. R., Lieberman, H. R., McNevin, N., & Ryan, D. H. (2003) · Nutritional Neuroscience

Sleep and Work-Related FatigueSleep and Wakefulness Research

Cited by 114

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 113

GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

Ryan, D., & Acosta, A. (2015) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 112

Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial

Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 110

Weight Loss Maintenance Following a Primary Care Intervention for Low‐income Minority Women

Martin, P. D., Dutton, G. R., Rhode, P. C., Horswell, R. L., Ryan, D. H., & Brantley, P. J. (2008) · Obesity

Obesity, Physical Activity, DietObesity and Health Practices

Cited by 100

Fiber Intake Predicts Weight Loss and Dietary Adherence in Adults Consuming Calorie-Restricted Diets: The POUNDS Lost (Preventing Overweight Using Novel Dietary Strategies) Study

Miketinas, D. C., Bray, G. A., Beyl, R. A., Ryan, D. H., Sacks, F. M., & Champagne, C. M. (2019) · The Journal of Nutrition

Nutritional Studies and DietFood composition and properties

Cited by 99

Update on obesity pharmacotherapy

Bray, G. A., & Ryan, D. H. (2014) · Annals of the New York Academy of Sciences

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 88

Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: Analysis of the look ahead randomized clinical trial

Look AHEAD Research Group, Yeh, H., Bantle, J. P., Cassidy‐Begay, M., Blackburn, G., Bray, G. A., Byers, T., Clark, J. M., Coday, M., Egan, C., et al. (2020) · Obesity

Cancer Risks and FactorsMetabolism, Diabetes, and Cancer

Cited by 82

Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies

Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 72

The impact of physical activity on the prevention of type 2 diabetes: Evidence and lessons learned from the Diabetes Prevention Program, a long-standing clinical trial incorporating subjective and objective activity measures

Kriska, A. M., Rockette-Wagner, B., Edelstein, S. L., Bray, G. A., Delahanty, L. M., Hoskin, M. A., Horton, E. S., Venditti, E. M., Knowler, W. C., DPP Research Group, et al. (2021) · Diabetes Care

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 70

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Ryan, D. H. (2021) · Journal of Obesity & Metabolic Syndrome

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 67

Effects of intensive lifestyle intervention on all-cause mortality in older adults with type 2 diabetes and overweight/obesity: results from the Look AHEAD Study

Look AHEAD Research Group, Wing, R. R., Bray, G. A., Cassidy-Begay, M., Clark, J. M., Coday, M., Egan, C., Evans, M., Foreyt, J. P., Glasser, S., et al. (2022) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 61

Adherence is a multi-dimensional construct in the POUNDS LOST trial

Williamson, D. A., Anton, S. D., Han, H., Champagne, C. M., Allen, R., LeBlanc, E., Ryan, D. H., McManus, K., Laranjo, N., Carey, V. J., et al. (2010) · Journal of Behavioral Medicine

Medication Adherence and ComplianceBehavioral Health and Interventions

Cited by 58

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 51

Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial

Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C., Craciun, A., Pall, D., et al. (2025) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 35

New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?

Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders

Pharmacology and Obesity TreatmentNutrition and Health in Aging

Cited by 34

The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact

Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 29